Objective: Research comparing hormone therapy (HT) doses, regimens, and routes of delivery in relation to cardiovascular disease (CVD) outcomes has been limited. This study directly compared different estrogen doses, routes of delivery, and HT formulations in postmenopausal women in relation to the risk of coronary heart disease (CHD), stroke, CVD mortality, total CVD, and all-cause mortality. Results: The mean follow-up was 10.4 years. In direct comparisons, oral estradiol was associated with lower hazard ratios (HRs) for stroke than oral conjugated equine estrogens (CEE; HR, 0.64; 95% CI, 0.40-1.02), but statistical power was limited. Similarly, transdermal estradiol was associated with a moderate but nonsignificantly lower risk of CHD compared with oral CEE (HR, 0.63; 95% CI, 0.37-1.06). For other outcomes, comparisons revealed no appreciable differences by estrogen doses, formulations, or routes of delivery. Absolute risks of CVD events and all-cause mortality were markedly lower in younger women compared with older women.
T he Women's Health Initiative clinical trial (WHI-CT) of oral estrogen plus progestin was stopped in 2002 (3 y earlier than planned) owing to an unfavorable balance of health benefits and risks when hormone therapy (HT) was used to prevent chronic disease. 1 The Women's Health Initiative (WHI) estrogen-alone trial also failed to demonstrate that treatment benefits exceeded risks under these conditions. 2 The HT prescribing guidelines of several professional organizations were revised to recommend the lowest effective HT dose for the shortest duration of time primarily for vasomotor symptom management rather than for chronic disease prevention. 3<5 As women continue to use HT for symptom management, the comparative safety of lower estrogen dosing, different formulations, and alternative routes of delivery with regard to cardiovascular disease (CVD) outcomes deserves further study. New lower-dose estrogens that can be administered orally or transdermally are now available and being increasingly used, but research on these regimens has been limited. Randomized clinical trial comparisons of differing HT regimens and clinical CVD outcomes are not available. In addition, previous observational studies have not been large enough or have not collected sufficiently detailed histories of HT use to provide head-to-head comparisons of different estrogen doses, formulations, and routes of delivery with respect to CVD events.
Hypothetically, lower-dose estrogen HT could be safer owing to lower dose-related adverse CVD effects. Furthermore, transdermal HT delivery avoids Bfirst-pass[ liver metabolism, which increases serum coagulation factors, triglycerides, C-reactive protein, and a host of other factors; it also provides a more physiologic ratio of estradiol to estrone. 6<9 The health effects of the addition of progestogens, used in combination HT for women with intact uterus, have only recently been compared with estrogen alone with respect to coronary heart disease (CHD), stroke, and other health outcomes. For example, CVD outcomes from the WHI estrogen-alone trial showed no increased risk of myocardial infarction, 10 whereas the WHI-CT of estrogen plus progestin demonstrated an overall increase in CVD risk. 11 This has led to speculation that the addition of a progestational agent to HT is a contributing factor for CVD risk.
Although both synthetic and bioidentical estrogens are effective for treating vasomotor symptoms, there are no data comparing these formulations in relation to CVD outcomes. Conjugated equine estrogens (CEE) have a complex composition with multiple biologically active estrogens and related steroids: estrone sulfate is believed to be the major active component. Whether there are differences in CVD outcomes related to CEE versus estradiolVpossibly related to differences in pharmacodynamic estrogen receptor affinity, metabolism, or other variablesVhas been suggested but has not been well explored. 12, 13 Several studies have demonstrated an elevated risk of CVD within the first 1 to 2 years of HT initiation. 1, 5, 11 Although we updated HT use during follow-up, the observational nature of the present study did not allow for a detailed examination of this relationship because many women had long-term use before enrollment. We did not include nonusers of HT in our analyses because of known confounding factors that influence the decision to use HT 14 and because our analyses were intended to offer insight into how alternative HT formulations compare with conventional-dose oral CEE on CVD outcomes.
Using data from the large-scale Women's Health Initiative Observational Study (WHI-OS) of 93,676 postmenopausal women, we performed direct comparisons between different estrogen doses, formulations, and routes of delivery, as well as the risks of major CHD, stroke, CVD mortality, total CVD (major CHD, stroke, and CVD mortality), and all-cause mortality. Furthermore, we analyzed the results by time since menopause (G10 vs Q10 y since menopause onset) and duration of HT use (G5 vs Q5 y) to determine whether the results varied by these factors.
METHODS
The WHI-OS is a large multicenter prospective cohort study that was conducted at 40 US sites. The details of the scientific rationale, eligibility criteria, and design of the WHI-OS have been previously published. 15 Briefly, 93,676 postmenopausal women with or without intact uterus, aged 50 to 79 years, were recruited between September 1994 and December 1998, with clinic visits at baseline and 3 years. Annual follow-up by mailed self-administered questionnaires included detailed assessments of HT medications and collection of information on medical risk factors, lifestyle risk factors, and incident clinical events. CVD events were confirmed by medical record review. The present analyses include follow-up through August 14, 2009 . Data were uniformly collected from participants by trained study staff according to a standardized institutional review boardYapproved protocol. All participants provided a written informed consent form for this research study at the time of enrollment.
As in previously published WHI research, 10 major CHD was defined as nonfatal clinical myocardial infarction or death due to CHD. CVD and mortality outcomes were confirmed by physician adjudicators. Stroke was defined as the rapid onset of a neurologic deficit lasting more than 24 hours, supported by imaging studies. Total CVD included major CHD, stroke, and CVD mortality. Venous thromboembolism was not included because of the absence of medical record confirmation of this outcome in the WHI-OS. HT oral CEE doses were defined as follows: low-dose CEE, less than 0.625 mg; conventional-dose CEE dose, 0.625 mg; high-dose CEE, more than 0.625 mg. Oral estrogen formulation categories included oral estradiol and oral CEE. Oral estrogen plus progestogen (E + P) users included the formulations of both oral CEE and oral estradiol with a progestin or progesterone. Transdermal estrogen categorization included all dose formulations, as well as the use of concomitant oral progestin or progesterone among women with intact uterus.
Statistical analysis
Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% CIs for different doses, routes of delivery, and formulations of HT as a time-varying exposure in relation to CVD outcomes, compared directly with conventional-dose oral CEE. Time to each CVD outcome was computed from the date of enrollment to the date of first CVD outcome event, and Bcensored[ was defined as excluded from further follow-up by date of last study follow-up or August 14, 2009 , whichever occurred first. Follow-up data on HT were collected from annual study questionnaires, with a mean follow-up time of 10.4 years. For each follow-up year, the type of hormone used was categorized as nonuser, estradiol, transdermal, oral low-dose CEE, oral conventional-dose CEE, conventional-dose CEE alone, E + P, and other. A variable for separate progestin or progesterone use was also created and adjusted for the analysis. All analyses were stratified by baseline 5-year age intervals and history of CVD, and adjusted for age (linear), race/ethnicity (white, black, Hispanic, Asian/ Pacific Islander, American Indian/Alaskan Native, other), and smoking (never, former, current). Variables considered as potential confounders or effect modifiers were included as covariates in the model: body mass index (BMI) categories (G25, 25 to G30, Q30 kg/m 2 ), BMI (linear), quartiles of total recreational physical activity, hypertension (never, untreated, treated), treated diabetes (no, yes), high cholesterol requiring medication or current use of lipid-lowering medication (no, yes), hysterectomy (no, yes), oophorectomy (no, partial, bilateral), educational attainment, and household income. Tests of proportional hazards assumption were conducted by testing the interaction terms of HT exposure, separately by dose and formulation, with time to the event or censoring for the five outcomes (major CHD, stroke, total CVD, CVD mortality, and all-cause mortality). All analyses were conducted using SAS version 9.2 (SAS Institute Inc, Cary, NC). All P values were two-sided tests, and values less than 0.05 were considered statistically significant. Table 1 summarizes the demographic characteristics of the cohort at baseline (study enrollment), stratified by comparison groups according to dose of CEE, HT formulation, and route of delivery. The mean duration of follow-up for the WHI-OS in these analyses was 10.4 years.
RESULTS
At baseline, 38,024 women (41% of the WHI-OS participants) had never used HT, and 13,931 (15%) reported past use at baseline and were excluded from this analysis. Among women currently using a CEE formulation, 2,149 (7%) were on low-dose CEE, 3,396 (11%) were on high-dose CEE, and the remainder (24,399; 82%) were on conventional-dose CEE. A total of 2,187 women were using transdermal estrogen. The mean (SD) age at enrollment was higher for women on lowdose CEE (65.3 [7.1] y) and lowest for users of transdermal estradiol (60.1 [6.6] y). Across categories of HT dose, formulation, and route of delivery, only small differences in baseline characteristics were observed.
The absolute risk of CVD events with conventional-dose HT with or without progestin or progesterone in women stratified by years since menopause is presented in Figure 1 . Overall, the absolute risk of CVD in younger women at close proximity to menopause was markedly lower than that in women distant from menopause. The test for the proportional hazards assumption was not violated.
Direct comparisons by route of delivery
Direct comparison of transdermal HT to oral conventionaldose CEE did not demonstrate significant differences for any of the CVD outcomes (Table 2) . However, a lower risk for major CHD with transdermal estrogen use (as compared with conventional-dose oral estrogen) was suggested, after adjustment for age, sociodemographic factors, lifestyle risk factors, and vascular risk factors (HR, 0.63; 95% CI, 0.37-1.06). This possible lower risk remained consistent within strata of years since menopause and duration of use (data not shown). Statistical power for direct comparisons by route of delivery and time since menopause or years of use, however, was limited.
Overall, the transdermal route of delivery was also associated with a nonsignificantly lower risk of stroke (HR, 0.87; 95% CI, 0.55-1.38) and total CVD (HR, 0.82; 95% CI, 0.59-1.14) compared with oral conventional-dose CEE, but risks for CVD mortality and all-cause mortality were similar to those for CEE ( Table 2) .
Direct comparisons by oral HT dose
Women who used oral low-dose HT had nonsignificantly lower rates of CHD, total CVD, and CVD mortality after multivariable adjustment, compared with women who used oral conventional-dose HT. This was not observed for stroke or all-cause mortality, however ( Table 2) .
Direct comparisons by HT formulation
Analysis by estrogen type (estradiol vs CEE) indicated that oral estradiol may be associated with a lower risk of stroke than conventional-dose oral CEE (HR, 0.64; 95% CI, 0.40-1.02), but the differences were not statistically significant (Table 3) . No significant differences in other CVD events were seen when we directly compared these formulations or when we compared combined E + P formulations with estrogen alone. In addition, results for these and other analyses did not differ substantially when stratified by number of years since menopause onset or duration of HT use (data not shown), but statistical power for such analyses was limited.
DISCUSSION
Our results indicate that CVD risk did not differ appreciably among women using different formulations, doses, and routes of administration of estrogen in comparison with conventional-dose oral CEE. Although similar rates were observed for most outcomes, oral estradiol may be associated with a lower risk of stroke, and transdermal HT and low-dose oral CEE may be linked to a lower risk of CHD, compared with conventional-dose oral CEE. The possibility that alternative formulations, doses, and routes of delivery may pose a lower risk of stroke and CHD than conventional-dose oral CEE is an important hypothesis that warrants confirmation in additional studies. The overall absolute risk of CVD and adverse events in younger women was much lower as compared with older women.
Our study is one of the first studies to provide head-to-head comparisons between the transdermal route of delivery and conventional-dose oral CEE on CVD outcomes. Although we found no statistically significant differences in CVD outcomes between these regimens, more favorable CHD findings with transdermal therapy were suggested. Additional research is needed to confirm these findings in view of the limited statistical power for these analyses. To date, large-scale randomized controlled trials of different HT formulations and risks of CVD events have not been conducted.
Our data add to emerging evidence suggesting that transdermal estrogen delivery may have advantages in minimizing the risk of CVD events associated with HT. A recent observational study of more than 80,000 women reported that oral, but not transdermal, HT carried an increased risk of stroke. 16 Transdermal treatments avoid the first-pass hepatic metabolism associated with an increase in thrombosis, although risks may be dose-dependent. The UK General Practice Research database found that the risk of stroke did not significantly increase with low-dose transdermal estradiol (dose formulation of 0.05 mg or lower), in contrast to an increased risk with higher transdermal and oral doses. 17 We did not have sufficient power to stratify transdermal regimens by dose in the current study.
The timing of HT initiation in relation to proximity to menopause has been recognized as a potentially important predictor of CVD outcomes. This Btiming hypothesis[ has been bolstered by observational studies and by some of the recent analyses from the WHI-CT showing that women who initiate HT closer to the menopausal transition tend to have more favorable CHD outcomes with HT than those initiating HT late in menopause. 18 Although we found similar HRs in younger and older women, our statistical power to address these issues was limited. Two recent clinical trials addressed the timing of HT initiation in relation to atherosclerosis progression, but they were not large enough to assess clinical CVD events. 19, 20 The strengths of our study include the large, diverse, and well-characterized study population with a broad distribution of HT doses and formulations. In addition, all CVD events and deaths were physician-adjudicated. Information was available on a large number of potential confounding factors, including traditional CVD risk factors, measured BMI, physical activity, other lifestyle factors, and socioeconomic status (educational attainment and household income), which, in addition to age, were included as covariates in the model.
The limitations of our study include the observational design that precludes causal inference. In view of the observational study design, we cannot exclude the possibility that confounding and selection factors related to the choice of HT formulation may have contributed to the CVD risk reductions.
A key difference between the WHI-OS and the WHI-CT, however, is that many of the women in the WHI-OS began HT closer to the onset of menopause, which may be less likely to precipitate CVD events than HT initiated in late menopause. In support of this, our current study results are generally concordant with the findings on the younger age groups studied in the WHI-CT. Another limitation is that we could not include venous thromboembolic events in our analyses owing to the absence of medical record confirmation of 0.98 (0.75-1.28) Major CHD refers to nonfatal myocardial infarction and CHD mortality. Total CVD refers to major CHD, stroke, and CVD mortality. Low-dose CEE is defined as less than 0.625 mg/day. Conventional-dose CEE is defined as 0.625 mg/day. HT, hormone therapy; CEE, conjugated equine estrogens; HR, hazard ratio; CHD, coronary heart disease; CVD, cardiovascular disease. a All HRs are from a Cox proportional hazards model stratified by baseline 5-year age intervals and history of CVD, and adjusted for age (linear), race/ethnicity (white, black, Hispanic, Asian/Pacific Islander, other), smoking (never, former, current), quartiles of total recreational physical activity, body mass index categories (G25, 25 to G30, Q30 kg/m 2 ), body mass index (linear), hypertension (never, untreated, treated), treated diabetes (no, yes), high cholesterol requiring medication or current use of lipid-lowering medication (no, yes), hysterectomy (no, yes), oophorectomy (no, partial, bilateral), education, and household income. this outcome in the WHI-OS, which may have led to underestimates of total CVD risk with HT. Moreover, only a small percentage of women were using transdermal or low-dose estrogen, so the statistical power to assess these associations and to fully disentangle differences attributable to formulation versus dose was limited. Finally, because transdermal estrogen and low-dose estrogen are relatively newer HT formulations, their use may be a surrogate for unmeasured confounding health variables associated with lower CVD rates, such as type of prescribing healthcare provider, healthcare system, or other health habits or attributes of the participants.
We recognize that our observational cohort may underestimate HT-related CVD risk by missing events during the first few years of HT initiation for women who began HT before enrollment into the WHI study. Previous randomized studies have reported an increased CVD risk with HT use that is divergent from observational results. 1, 5, 11, 21 With regard to stroke, randomized trials and observational studies have been concordant, showing an overall increased risk with HT. 3, 5 Our study thus offers further insights into stroke risk based on findings according to estrogen formulation and route of delivery.
CONCLUSIONS
Our results suggest that among women using HT, the dose, formulation, and route of delivery are not associated with substantially different risks of CVD outcomes. However, transdermal and oral estradiol may be associated with lower CHD and stroke risks, respectively, as compared with conventional-dose oral CEE. Results for low-dose oral CEE also seem more favorable than results for conventional-dose oral CEE for some CVD events, although the differences are not statistically significant. Our data support a growing body of literature suggesting that the transdermal route of delivery and/or lower doses of estrogen may avoid the excess risk of certain CVD events associated with HT. Despite our current findings, systemic HT should be used only for menopausal symptom management or, in selected women, prevention of osteoporosis (and not for CVD prevention), given its complex balance of benefits and risks. However, these results are potentially relevant to a very large population of women transitioning through menopause who require HT for symptom control. Additional research is needed to confirm or refute the comparative safety of diverse HT options. 1.14 (0.95-1.37) Total CVD refers to total CHD, stroke, and CVD mortality. Major CHD refers to nonfatal myocardial infarction and CHD mortality. Conventional-dose CEE is defined as 0.625 mg/day. Oral E + P includes the formulations of both oral CEE and oral estradiol with a progestin or progesterone. E + P, estrogen plus progestogen; CEE, conjugated equine estrogens; HT, hormone therapy; HR, hazard ratio; CHD, coronary heart disease; CVD, cardiovascular disease. a All HRs are from a Cox proportional hazards model stratified by baseline 5-year age intervals and history of CVD, and adjusted for age (linear), race/ethnicity (white, black, Hispanic, Asian/Pacific Islander, other), smoking (never, former, current), quartiles of total recreational physical activity, body mass index categories (G25, 25 to G30, Q30 kg/m 2 ), body mass index (linear), hypertension (never, untreated, treated), treated diabetes (no, yes), high cholesterol requiring medication or current use of lipid-lowering medication (no, yes), hysterectomy (no, yes), oophorectomy (no, partial, bilateral), education, and household income.
